BMY - Bristol-Myers Squibb Company

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day.

• 
  Eli Lilly (LLY) Gains But Lags Market: What You Should Know

  Zacks
• 
  Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

  Zacks

Here's Why Bristol-Myers Squibb (NYSE:BMY) Has Caught The Eye Of Investors

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.

3 Dividend Stocks You Can Buy Without Any Hesitation

Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb):  Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.

Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 78% of the company

Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...

The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.

• 
  Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

  Zacks
• 
  Eli Lilly (LLY) Gains But Lags Market: What You Should Know

  Zacks

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

3 Top Stocks That Just Went on Sale

Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

Is Bristol Myers Squibb a Top Dividend Stock?

Its hefty yield isn't the only reason to consider buying this top pharma stock.

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.

Bristol-Myers Squibb (NYSE:BMY) sheds 3.3% this week, as yearly returns fall more in line with earnings growth

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

1 Dirt Cheap Dividend Stock to Buy in May

Let's consider the case of Bristol Myers Squibb (NYSE: BMY). The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb.

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Is Bristol-Myers Squibb Stock a Buy Now?

Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest.

3 High-Yielding Dividend Stocks That Could Pay You Forever

There has been no shortage of companies cutting dividends in the past year. If you're looking for some safety on the dividend front, consider Bristol Myers Squibb (NYSE: BMY), Verizon Communications (NYSE: VZ), and Coca-Cola (NYSE: KO).

Bristol-Myers Squibb Insiders Sell US$38m Of Stock, Possibly Signalling Caution \

In the last year, many Bristol-Myers Squibb Company ( NYSE:BMY ) insiders sold a substantial stake in the company which...

3 Things About Bristol-Myers Squibb That Smart Investors Know

When it comes to large and fairly complicated companies such as Bristol-Myers Squibb, (NYSE: BMY), the most knowledgeable investors tend to see a lot of things that casual observers miss. With that perspective in hand, let's explore three less-than-obvious things about Bristol-Myers that smart investors probably know, so that you'll have the benefit of their observations. Smart investors appreciate that Bristol-Myers isn't going to be expanding very much in the near term as a result of one of its big-earning medicines losing its exclusivity protections.